| DFS | Overall survival | ||||
---|---|---|---|---|---|---|
 | HR | 95% CI | P-value | HR | 95% CI | P-value |
Menopausal status | Â | 1.075 to 3.064 | Â | Â | 1.027 to 3.836 | Â |
Post vs Pre | 1.815 | Â | 0.026 | 1.985 | Â | 0.041 |
Tumor status | Â | 1.304 to 4.419 | Â | Â | 1.710 to 11.114 | Â |
T2/T3 vs T1 | 2.401 | Â | 0.005 | 4.359 | Â | 0.002 |
Nodes | Â | 1.418 to 3.832 | Â | Â | 1.527 to 5.207 | Â |
N> 3 vs N0-3 | 2.331 | Â | 0.001 | 2.819 | Â | 0.001 |
Histology grade | Â | 0.989 to 2.805 | Â | Â | 0.644 to 2.390 | Â |
3 vs 1/2 | 1.665 | Â | 0.055 | 1.240 | Â | 0.520 |
HR | Â | 0.454 to 1.504 | Â | Â | 0.585 to 2.387 | Â |
ER(-)/PR(-) vs other | 0.826 | Â | 0.533 | 1.182 | Â | 0.641 |
Triple negative | Â | 0.454 to 1.681 | Â | Â | 0.492 to 2.348 | Â |
ER(-)/PR(-)/HER-2 vs Other | 0.874 | Â | 0.686 | 1.075 | Â | 0.856 |
Hormonotherapy | Â | 0.696 to 3.759 | Â | Â | 0.442 to 4.687 | Â |
No vs Yes | 1.618 | Â | 0.264 | 1.439 | Â | 0.546 |
Chemotherapy | CMF (ref) | Â | 0.589 to 3.812 | Â | Â | 0.352 to 2.976 |
FEC | Â | Â | 0.339 | Â | Â | 0.911 |
T/EC | 1.498 | 0.389 to 2.745 | 0.396 | 1.024 | 0.388 to 3.564 | 0.966 |
 | 1.034 |  | 0.947 | 1.176 |  | 0.775 |
CK-19 at five years FU Persistently negative Turn to negative Turn to positive Persistently positive (ref) | 0.300 0.201 0.498 | 0.144 to 0.623 0.079 to 0.513 0.264 to 0.939 | 0.001 0.001 0.031 < 0.001 | 0.318 0.260 0.582 | 0.121 to 0.836 0.078 to 0.868 0.271 to 1.253 | 0.020 0.028 0.167 0.025 |